Vertex Pharmaceuticals has signed a long-term supply agreement with Lonza to manufacture its gene therapy Casgevy. The US Food and Drug Administration approved the treatment for sickle cell disease in ...

Lonza has extended its antibody-drug conjugate (ADC) manufacturing contract with a major biopharmaceutical customer, according to a press statement, which does not name the client. Lonza says that as ...

Vaxcyte (NASDAQ:PCVX) and Lonza (OTCPK:LZAGY) (OTCPK:LZAGF) expanded their collaboration by signing a new commercial manufacturing agreement for pneumococcal conjugate vaccines (PCV). The contract ...

Lone Star Funds, Altaris LLC and One Rock Capital Partners are among shortlisted bidders for Lonza Group AG’s capsules and health ingredients business, according to people familiar with the matter.

Lonza plans to spend another 500 million Swiss francs ($562.3 million) to upgrade the facility in Vacaville, which makes monoclonal antibodies from genetically modified living cells, to produce a new ...